Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

This study aimed to evaluate the association between pre-treatment vitamin D levels and the incidence of severe CIPN in breast cancer patients receiving paclitaxel-based chemotherapy.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cohort study.

Cohort study

Examines exposures and outcomes over time within a defined group.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Pre-treatment vitamin D insufficiency predicts severe paclitaxel-induced sensory neuropathy in breast cancer patients: a prospective cohort study

Source: Article title.

Participants were stratified into three mutually exclusive groups based on serum 25(OH)D levels.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Pre-treatment vitamin D insufficiency predicts severe paclitaxel-induced sensory neuropathy in breast cancer patients: a prospective cohort study

Cohort study · Scientific Reports · 2026

Original publication title

Pre-treatment vitamin D insufficiency predicts severe paclitaxel-induced sensory neuropathy in breast cancer patients: a prospective cohort study

Amany M. Elfeky; Muhammad I. El-Masry; Amr A. Mahmoud; Sara A. Amin; Rana El Falah; Mo’men M. Saadoun

© The Author(s) 2026

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Paclitaxel-induced peripheral neuropathy (CIPN) is a debilitating side effect affecting up to 70% of patients receiving paclitaxel chemotherapy, with severe symptoms occurring in approximately 30%. While non-modifiable risk factors such as age and genetics have been established, the role of modifiable factors, including vitamin D insufficiency, remains poorly characterized. This study aimed to evaluate the association between pre-treatment vitamin D levels and the incidence of severe CIPN in breast cancer patients receiving paclitaxel-based chemotherapy. A prospective cohort study was conducted on 300 breast cancer patients (stage I-III) receiving paclitaxel-based chemotherapy (80 mg/m²) for 12 weeks at Kafrelsheikh University Hospitals.

Baseline serum 25(OH)D was quantified using the Elecsys Vitamin D Total II assay on the Cobas e411 platform, standardized to the VDSP reference method. Pre-treatment vitamin D levels were measured using liquid chromatography-tandem mass spectrometry (LC-MS/MS), with insufficiency defined as ≤ 20 ng/mL. CIPN was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20-item scale (EORTC QLQ-CIPN20), with particular focus on grade 3 to 4 sensory neuropathy. Statistical analyses included receiver operating characteristic (ROC) curves and multivariate logistic regression to identify independent risk factors.

The mean pre-treatment vitamin D level was 23.45 ± 8.3 ng/mL, with 39.3% (118/300) of patients classified as having vitamin D insufficiency. Patients with vitamin D insufficiency demonstrated significantly higher rates of grade 3 to 4 sensory CIPN compared to those with sufficient levels (32.2% vs. 5.5%, p < 0.001). Mean vitamin D levels were significantly lower in patients who developed severe CIPN (17.5 ± 4.9 ng/mL vs. 24.6 ± 8.4 ng/mL, p < 0.001). ROC analysis demonstrated vitamin D’s predictive value for motor CIPN (AUC = 0.747, p = 0.038).

Multivariate logistic regression analysis confirmed vitamin D insufficiency as an independent predictor of sensory CIPN (OR = 6.72, 95% CI: 3.09 to 14.61, p < 0.001), even after adjusting for age, body mass index, and treatment schedule. Vitamin D insufficiency is independently associated with an increased risk of severe paclitaxel-induced peripheral neuropathy in breast cancer patients. While causal inference cannot be drawn from this observational design, these findings provide a strong rationale for future randomized controlled trials to evaluate whether vitamin D supplementation could serve as a candidate preventive strategy to mitigate CIPN severity and optimize cancer therapy outcomes.

Supplementary Information

The online version contains supplementary material available at 10.1038/s41598-026-50367-8.

Authors’ abstract

Paclitaxel-induced peripheral neuropathy (CIPN) is a debilitating side effect affecting up to 70% of patients receiving paclitaxel chemotherapy, with severe symptoms occurring in approximately 30%. While non-modifiable risk factors such as age and genetics have been established, the role of modifiable factors, including vitamin D insufficiency, remains poorly characterized. This study aimed to evaluate the association between pre-treatment vitamin D levels and the incidence of severe CIPN in breast cancer patients receiving paclitaxel-based chemotherapy. A prospective cohort study was conducted on 300 breast cancer patients (stage I-III) receiving paclitaxel-based chemotherapy (80 mg/m²) for 12 weeks at Kafrelsheikh University Hospitals.

Baseline serum 25(OH)D was quantified using the Elecsys Vitamin D Total II assay on the Cobas e411 platform, standardized to the VDSP reference method. Pre-treatment vitamin D levels were measured using liquid chromatography-tandem mass spectrometry (LC-MS/MS), with insufficiency defined as ≤ 20 ng/mL. CIPN was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20-item scale (EORTC QLQ-CIPN20), with particular focus on grade 3 to 4 sensory neuropathy. Statistical analyses included receiver operating characteristic (ROC) curves and multivariate logistic regression to identify independent risk factors.

The mean pre-treatment vitamin D level was 23.45 ± 8.3 ng/mL, with 39.3% (118/300) of patients classified as having vitamin D insufficiency. Patients with vitamin D insufficiency demonstrated significantly higher rates of grade 3 to 4 sensory CIPN compared to those with sufficient levels (32.2% vs. 5.5%, p < 0.001). Mean vitamin D levels were significantly lower in patients who developed severe CIPN (17.5 ± 4.9 ng/mL vs. 24.6 ± 8.4 ng/mL, p < 0.001). ROC analysis demonstrated vitamin D’s predictive value for motor CIPN (AUC = 0.747, p = 0.038).

Multivariate logistic regression analysis confirmed vitamin D insufficiency as an independent predictor of sensory CIPN (OR = 6.72, 95% CI: 3.09 to 14.61, p < 0.001), even after adjusting for age, body mass index, and treatment schedule. Vitamin D insufficiency is independently associated with an increased risk of severe paclitaxel-induced peripheral neuropathy in breast cancer patients. While causal inference cannot be drawn from this observational design, these findings provide a strong rationale for future randomized controlled trials to evaluate whether vitamin D supplementation could serve as a candidate preventive strategy to mitigate CIPN severity and optimize cancer therapy outcomes.

Supplementary Information

The online version contains supplementary material available at 10.1038/s41598-026-50367-8.

Publication and source details

Original title: Pre-treatment vitamin D insufficiency predicts severe paclitaxel-induced sensory neuropathy in breast cancer patients: a prospective cohort study

Amany M. Elfeky; Muhammad I. El-Masry; Amr A. Mahmoud; Sara A. Amin; Rana El Falah; Mo’men M. Saadoun

Scientific Reports · 2026

© The Author(s) 20262026https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Kafr El Shiekh University

Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T10:39:09.685199+00:00

DOI: 10.1038/s41598-026-50367-8 · PMC13144410